Cysteine-lowering treatment with mesna against obesity: Proof of concept and results from a human phase I, dose-finding study.

导出 OA

翻译打印收藏纠错

第一作者： Kathrine J,Vinknes

第一单位： Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

作者： Kathrine J,Vinknes ^[1] ; Thomas,Olsen ^[1] ; Hasse Khiabani,Zaré ^[2] ; Nasser E,Bastani ^[1] ; Emma,Stolt ^[1] ; Anja F,Dahl ^[1] ; Roger D,Cox ^[3] ; Helga,Refsum ^[4] ; Kjetil,Retterstøl ^[5] ; Anders,Åsberg ^[6] ; Amany,Elshorbagy ^[7]

作者单位： Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. ^[1] Department of Pharmacology, Oslo University Hospital, Oslo, Norway. ^[2] MRC Harwell Institute, Mammalian Genetics Unit, Harwell Campus, Oxford, UK. ^[3] Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.;Department of Pharmacology, University of Oxford, Oxford, UK. ^[4] Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.;The Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway. ^[5] Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.;Department of Pharmacy, University of Oslo, Oslo, Norway. ^[6] Department of Pharmacology, University of Oxford, Oxford, UK.;Department of Physiology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt. ^[7]

关键词 antiobesity drug body composition clinical trial mouse model pharmacodynamics phase I study